|Articles|April 29, 2010
NewCardio to Perform First Revenue-Generating QT Study Using QTinno
Advertisement
NewCardio, Inc.
, (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced that a global biopharmaceutical services provider has signed a MSA, licensing NewCardio's QTinno™ software solution to enhance its delivery of fully automated cardiac safety analyses for early phase QT studies. The CRO is expected to deploy QTinno in several clinical unit locations worldwide.
In addition, the CRO has signed a services work order related to the first study using QTinno, which is scheduled to be initiated this June.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
2
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
3
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
4
ACT Brief: Funding Gaps and Indication Decisions in Early-Stage Programs, Recruitment Funnel Leak Diagnosis, and Mega-Merger Speculation Denial
5